PeptideCompareSS-31 (Elamipretide) — the cardiolipin protector.
SS-31 (Elamipretide, MTP-131) is a mitochondria-targeting tetrapeptide that selectively concentrates in the inner mitochondrial membrane, binding cardiolipin to stabilise energy production. It has advanced furthest in clinical trials of the mitochondrial peptides.
What is SS-31 (Elamipretide)?
SS-31 is a synthetic tetrapeptide that crosses cell membranes and concentrates 1000-5000x in the inner mitochondrial membrane, where it binds cardiolipin — a phospholipid essential for the electron transport chain. By stabilising cardiolipin, SS-31 improves mitochondrial efficiency and reduces reactive oxygen species. It has been studied clinically (as Elamipretide) for mitochondrial diseases, heart failure and rare conditions like Barth syndrome.
What does the research show?
What to look for when buying in Europe
One of the more clinically advanced peptides in this category. Require ≥98% HPLC purity and a batch-matched COA from a named lab. PeptideCompare tracks several EU vendors.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.
Compare SS-31 (Elamipretide) across EU suppliers
6 EU vendors · COA-verified · from €39.95 · Updated monthly
Frequently asked questions
What is SS-31 (Elamipretide)? ▾
SS-31 is a synthetic tetrapeptide that crosses cell membranes and concentrates in the inner mitochondrial membrane, where it binds cardiolipin, a phospholipid essential for the electron transport chain. Stabilising cardiolipin improves mitochondrial efficiency and reduces reactive oxygen species.
What does the research show? ▾
There is strong mechanistic and animal evidence for cardiolipin stabilisation and improved ATP production, and it reached late-stage clinical trials, as Elamipretide, for heart failure and Barth syndrome with mixed primary-endpoint results.
How does SS-31 protect mitochondria? ▾
By concentrating in the inner mitochondrial membrane and binding cardiolipin, it stabilises the electron transport chain, improving efficiency and lowering reactive oxygen species.
Is SS-31 the same as Elamipretide? ▾
Yes. SS-31 is also known as Elamipretide (MTP-131), the name under which it has been studied clinically.
What conditions has SS-31 been studied for? ▾
It has been studied clinically for mitochondrial diseases, heart failure and rare conditions such as Barth syndrome, with mixed clinical results.
Is SS-31 legal in the EU? ▾
It is sold as a research compound for laboratory use only.
References
- Accelerated approval of FORZINITY (elamipretide) to improve muscle strength in Barth syndrome at 30 kg or more. The approval rests on an intermediate endpoint, knee extensor strength, and was contested: FDA staff had earlier stated the evidence did not establish effectiveness, and the advisory committee split 10 to 6. U.S. FDA. Integrated Review, NDA 215244 (elamipretide), 19 September 2025. FDA review
- The randomised, double-blind, placebo-controlled phase 2 trial supporting the approval, together with its open-label extension. The patient numbers are very small — Barth syndrome affects roughly 150 people in the United States. TAZPOWER trial, ClinicalTrials.gov NCT03098797. NCT03098797